The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Exploratory Analysis of TP53 Mutations in Circulating Tumour DNA as Biomarkers of Treatment Response for Patients with Relapsed High-Grade Serous Ovarian Carcinoma: A Retrospective Study
Open accessAbstract
BACKGROUND: Circulating tumour DNA (ctDNA) carrying tumour-specific sequence alterations may provide a minimally invasive means to dynamically assess tumour burden and response to treatment in cancer patients. Somatic TP53 mutations are a defining feature of high-grade serous ovarian carcinoma (HGSOC). We tested whether these mutations could be used as personalised markers to monitor tumour burden and early changes as a predictor of response and time to progression (TTP). METHODS AND FINDINGS: We performed a retrospective analysis of serial plasma samples collected during routine clinical visits from 40 patients with HGSOC undergoing heterogeneous standard of care treatment. Patient-specific TP53 assays were developed for 31 unique mutations identified in formalin-fixed paraffin-embedded tumour DNA from these patients. These assays were used to quantify ctDNA in 318 plasma samples using microfluidic digital PCR. The TP53 mutant allele fraction (TP53MAF) was compared to serum CA-125, the current gold-standard response marker for HGSOC in blood, as well as to disease volume on computed tomography scans by volumetric analysis. Changes after one cycle of treatment were compared with TTP. The median TP53MAF prior to treatment in 51 relapsed treatment courses was 8% (interquartile range [IQR] 1.2%-22%) compared to 0.7% (IQR 0.3%-2.0%) for seven untreated newly diagnosed stage IIIC/IV patients. TP53MAF correlated with volumetric measurements (Pearson r = 0.59, p < 0.001), and this correlation improved when patients with ascites were excluded (r = 0.82). The ratio of TP53MAF to volume of disease was higher in relapsed patients (0.04% per cm3) than in untreated patients (0.0008% per cm3, p = 0.004). In nearly all relapsed patients with disease volume > 32 cm3, ctDNA was detected at ≥20 amplifiable copies per millilitre of plasma. In 49 treatment courses for relapsed disease, pre-treatment TP53MAF concentration, but not CA-125, was associated with TTP. Response to chemotherapy was seen earlier with ctDNA, with a median time to nadir of 37 d (IQR 28-54) compared with a median time to nadir of 84 d (IQR 42-116) for CA-125. In 32 relapsed treatment courses evaluable for response after one cycle of chemotherapy, a decrease in TP53MAF of >60% was an independent predictor of TTP in multivariable analysis (hazard ratio 0.22, 95% CI 0.07-0.67, p = 0.008). Conversely, a decrease in TP53MAF of ≤60% was associated with poor response and identified cases with TTP < 6 mo with 71% sensitivity (95% CI 42%-92%) and 88% specificity (95% CI 64%-99%). Specificity was improved when patients with recent drainage of ascites were excluded. Ascites drainage led to a reduction of TP53MAF concentration. The limitations of this study include retrospective design, small sample size, and heterogeneity of treatment within the cohort. CONCLUSIONS: In this retrospective study, we demonstrated that ctDNA is correlated with volume of disease at the start of treatment in women with HGSOC and that a decrease of ≤60% in TP53MAF after one cycle of chemotherapy was associated with shorter TTP. These results provide evidence that ctDNA has the potential to be a highly specific early molecular response marker in HGSOC and warrants further investigation in larger cohorts receiving uniform treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
von Elm, E., Altman, D. G., Egger, M., Pocock, S. J., Gøtzsche, P. C., Vandenbroucke, J. P., & Initiative, F. T. S. (2007) · PLoS Medicine · doi:10.1371/journal.pmed.0040296 · Cited by 23,020
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Detection of Circulating Tumor DNA in Early- and Late-Stage Human Malignancies
Bettegowda, C., Sausen, M., Leary, R. J., Kinde, I., Wang, Y., Agrawal, N., Bartlett, B. R., Wang, H., Luber, B., Alani, R. M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3007094 · Cited by 5,067
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Circulating mutant DNA to assess tumor dynamics
Diehl, F., Schmidt, K., Choti, M. A., Romans, K., Goodman, S., Li, M., Thornton, K., Agrawal, N., Sokoll, L., Szabo, S. A., et al. (2008) · Nature Medicine · doi:10.1038/nm.1789 · Cited by 2,734
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage
Newman, A. M., Bratman, S. V., To, J., Wynne, J. F., Eclov, N. C. W., Modlin, L. A., Liu, C. L., Neal, J. W., Wakelee, H. A., Merritt, R. E., et al. (2014) · Nature Medicine · doi:10.1038/nm.3519 · Cited by 2,220
Liquid Biopsies: Genotyping Circulating Tumor DNA
Diaz, L. A., & Bardelli, A. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.2011 · Cited by 2,210
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
Dawson, S.-J., Tsui, D. W. Y., Murtaza, M., Biggs, H., Rueda, O. M., Chin, S.-F., Dunning, M. J., Gale, D., Forshew, T., Mahler-Araujo, B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1213261 · Cited by 2,207
Self-citationReporting Recommendations for Tumor Marker Prognostic Studies (REMARK)
McShane, L. M., Altman, D. G., Sauerbrei, W., Taube, S. E., Gion, M., & Clark, G. M. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji237 · Cited by 2,162
Liquid biopsy: monitoring cancer-genetics in the blood
Crowley, E., Di Nicolantonio, F., Loupakis, F., & Bardelli, A. (2013) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2013.110 · Cited by 1,819
Reactivity of a monoclonal antibody with human ovarian carcinoma.
Bast, R. C., Feeney, M., Lazarus, H., Nadler, L. M., Colvin, R. B., & Knapp, R. C. (1981) · Journal of Clinical Investigation · doi:10.1172/jci110380 · Cited by 1,661
Buys, S. S. (2011) · JAMA · doi:10.1001/jama.2011.766 · Cited by 1,323
Forshew, T., Murtaza, M., Parkinson, C., Gale, D., Tsui, D. W. Y., Kaper, F., Dawson, S.-J., Piskorz, A. M., Jimenez-Linan, M., Bentley, D., et al. (2012) · Science Translational Medicine · doi:10.1126/scitranslmed.3003726 · Cited by 1,297
Self-citationDetection and quantification of mutations in the plasma of patients with colorectal tumors
Diehl, F., Li, M., Dressman, D., He, Y., Shen, D., Szabo, S., Diaz, L. A., Goodman, S. N., David, K. A., Juhl, H., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0507904102 · Cited by 1,188
Sturgeon, C. M., Duffy, M. J., Stenman, U.-H., Lilja, H., Brünner, N., Chan, D. W., Babaian, R., Bast, R. C., Dowell, B., Esteva, F. J., et al. (2008) · Clinical Chemistry · doi:10.1373/clinchem.2008.105601 · Cited by 1,129
Spatial and temporal diversity in genomic instability processes defines lung cancer evolution
de Bruin, E. C., McGranahan, N., Mitter, R., Salm, M., Wedge, D. C., Yates, L., Jamal-Hanjani, M., Shafi, S., Murugaesu, N., Rowan, A. J., et al. (2014) · Science · doi:10.1126/science.1253462 · Cited by 1,117
Jacobs, I. J., Menon, U., Ryan, A., Gentry-Maharaj, A., Burnell, M., Kalsi, J. K., Amso, N. N., Apostolidou, S., Benjamin, E., Cruickshank, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01224-6 · Cited by 1,048
JACOBS, I., ORAM, D., FAIRBANKS, J., TURNER, J., FROST, C., & GRUDZINSKAS, J. G. (1990) · BJOG: An International Journal of Obstetrics & Gynaecology · doi:10.1111/j.1471-0528.1990.tb02448.x · Cited by 962
Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin.
Markman, M., Rothman, R., Hakes, T., Reichman, B., Hoskins, W., Rubin, S., Jones, W., Almadrones, L., & Lewis, J. L. (1991) · Journal of Clinical Oncology · doi:10.1200/jco.1991.9.3.389 · Cited by 839
Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary
Ahmed, A. A., Etemadmoghadam, D., Temple, J., Lynch, A. G., Riad, M., Sharma, R., Stewart, C., Fereday, S., Caldas, C., deFazio, A., et al. (2010) · The Journal of Pathology · doi:10.1002/path.2696 · Cited by 787
Self-citationCirculating Tumor Cells and Response to Chemotherapy in Metastatic Breast Cancer: SWOG S0500
Smerage, J. B., Barlow, W. E., Hortobagyi, G. N., Winer, E. P., Leyland-Jones, B., Srkalovic, G., Tejwani, S., Schott, A. F., O'Rourke, M. A., Lew, D. L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2561 · Cited by 648
Tie, J., Kinde, I., Wang, Y., Wong, H. L., Roebert, J., Christie, M., Tacey, M., Wong, R., Singh, M., Karapetis, C. S., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv177 · Cited by 635
Soluble normal and mutated DNA sequences from single-copy genes in human blood.
Sorenson, G. D., Pribish, D. M., Valone, F. H., Memoli, V. A., Bzik, D. J., & Yao, S. (1994) · PubMed · Cited by 530
Vasioukhin, V., Anker, P., Maurice, P., Lyautey, J., Lederrey, C., & Stroun, M. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb04828.x · Cited by 414
Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis
Schwarz, R. F., Ng, C. K. Y., Cooke, S. L., Newman, S., Temple, J., Piskorz, A. M., Gale, D., Sayal, K., Murtaza, M., Baldwin, P. J., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001789 · Cited by 400
Self-citationOptimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma
Köbel, M., Piskorz, A. M., Lee, S., Lui, S., LePage, C., Marass, F., Rosenfeld, N., Mes Masson, A., & Brenton, J. D. (2016) · The Journal of Pathology: Clinical Research · doi:10.1002/cjp2.53 · Cited by 387
Self-citationYung, T. K. F., Chan, K. C. A., Mok, T. S. K., Tong, J., To, K.-F., & Lo, Y. M. D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2622 · Cited by 385
Re: New Guidelines to Evaluate the Response to Treatment in Solid Tumors (Ovarian Cancer)
Rustin, G. J. S., Quinn, M., Thigpen, T., du Bois, A., Pujade-Lauraine, E., Jakobsen, A., Eisenhauer, E., Sagae, S., Greven, K., Vergote, I., et al. (2004) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djh081 · Cited by 378
Van Gorp, T., Cadron, I., Despierre, E., Daemen, A., Leunen, K., Amant, F., Timmerman, D., De Moor, B., & Vergote, I. (2011) · British Journal of Cancer · doi:10.1038/sj.bjc.6606092 · Cited by 354
Eisenhauer, E. A., Vermorken, J. B., & van Glabbeke, M. (1997) · Annals of Oncology · doi:10.1023/a:1008240421028 · Cited by 265
Blackledge, G., Lawton, F., Redman, C., & Kelly, K. (1989) · British Journal of Cancer · doi:10.1038/bjc.1989.132 · Cited by 255
Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer
Sölétormos, G., Duffy, M. J., Hassan, S. O. A., Verheijen, R. H. M., Tholander, B., Bast, R. C., Gaarenstroom, K. N., Sturgeon, C. M., Bonfrer, J. M., Petersen, P. H., et al. (2016) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000586 · Cited by 255
Markman, M., Markman, J., Webster, K., Zanotti, K., Kulp, B., Peterson, G., & Belinson, J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.05.195 · Cited by 220
Role of CA125 in predicting ovarian cancer survival - a review of the epidemiological literature
Gupta, D., & Lis, C. G. (2009) · Journal of Ovarian Research · doi:10.1186/1757-2215-2-13 · Cited by 208
To, E. W. H., Chan, K. C. A., Leung, S. F., Chan, L. Y. S., To, K., Chan, A. T. �., Johnson, P. J., & Lo, Y. M. D. (2003) · PubMed · Cited by 189
Pereira, E., Camacho-Vanegas, O., Anand, S., Sebra, R., Catalina Camacho, S., Garnar-Wortzel, L., Nair, N., Moshier, E., Wooten, M., Uzilov, A., et al. (2015) · PLOS ONE · doi:10.1371/journal.pone.0145754 · Cited by 180
Jamal-Hanjani, M., Wilson, G. A., Horswell, S., Mitter, R., Sakarya, O., Constantin, T., Salari, R., Kirkizlar, E., Sigurjonsson, S., Pelham, R., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw037 · Cited by 170
Perspective: A Program to Improve Protein Biomarker Discovery for Cancer
Aebersold, R., Anderson, L., Caprioli, R., Druker, B., Hartwell, L., & Smith, R. (2005) · Journal of Proteome Research · doi:10.1021/pr050027n · Cited by 161
Circulating free DNA concentration is an independent prognostic biomarker in lung cancer
Tissot, C., Toffart, A., Villar, S., Souquet, P.-J., Merle, P., Moro‐Sibilot, D., Pérol, M., Zavadil, J., Brambilla, C., Olivier, M., et al. (2015) · European Respiratory Journal · doi:10.1183/13993003.00676-2015 · Cited by 141
Tumor-specific p53 sequences in blood and peritoneal fluid of women with epithelial ovarian cancer
Swisher, E. M., Wollan, M., Mahtani, S. M., Willner, J. B., Garcia, R. L., Goff, B. A., & King, M. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2005.01.054 · Cited by 130
Serum and tissue biomarkers as predictive and prognostic variables in epithelial ovarian cancer
Gadducci, A., Cosio, S., Tana, R., & Genazzani, A. R. (2008) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2008.05.001 · Cited by 98
CHIEN, J. R., Sicotte, H., Fan, J., Humphray, S., Cunningham, J. M., Kalli, K. R., Oberg, A. L., Hart, S. N., Li, Y., Davila, J. I., et al. (2015) · Nucleic Acids Research · doi:10.1093/nar/gkv111 · Cited by 56
Cell-free DNA level as a prognostic biomarker for epithelial ovarian cancer.
No, J. H., Kim, K., Park, K. H., & Kim, Y. B. (2012) · PubMed · Cited by 52
A Bayesian adaptive design for biomarker trials with linked treatments
Wason, J. M. S., Abraham, J., Baird, R. D., Gournaris, I., Vallier, A.-L., Brenton, J. D., Earl, H. M., & Mander, A. (2015) · British Journal of Cancer · doi:10.1038/bjc.2015.278 · Cited by 45
Self-citationDetection of p53 mutations in the plasma DNA of patients with ovarian cancer
Otsuka, J., Okuda, T., Sekizawa, A., Amemiya, S., Saito, H., Okai, T., & Kushima, M. (2004) · International Journal of Gynecological Cancer · doi:10.1111/j.1048-891x.2004.014305.x · Cited by 45
Lee, C. K., Simes, R. J., Brown, C. S. B., Gebski, V., Pfisterer, J., Swart, A. M., Berton-Rigaud, D., Plante, M., Skeie-Jensen, T., Vergote, I. B., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mds538 · Cited by 43
Rockall, A., Avril, N. E., Lam, R., Iannone, R., Mozley, P. D., Parkinson, C., Bergstrom, D., Sala, E., Sarker, S., McNeish, I. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2634 · Cited by 40
Self-citationPrognostic factors modifying the treatment-free interval in recurrent ovarian cancer
Eng, K. H., Hanlon, B. M., Bradley, W. H., & Szender, J. B. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.09.011 · Cited by 36
Archibald, K. M., Kulbe, H., Kwong, J., Chakravarty, P., Temple, J., Chaplin, T., Flak, M. B., McNeish, I. A., Deen, S., Brenton, J. D., et al. (2012) · Oncogene · doi:10.1038/onc.2011.653 · Cited by 26
Self-citation
Cited by
Liquid biopsies come of age: Towards implementation of circulating tumour DNA
Wan, J. C. M., Massie, C., Garcia-Corbacho, J., Mouliere, F., Brenton, J. D., Caldas, C., Pacey, S., Baird, R., & Rosenfeld, N. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2017.7 · Cited by 2,809
Self-citationCurrent and future perspectives of liquid biopsies in genomics-driven oncology
Heitzer, E., Haque, I. S., Roberts, C. E. S., & Speicher, M. R. (2019) · Nature Reviews Genetics · doi:10.1038/s41576-018-0071-5 · Cited by 1,557
Enhanced detection of circulating tumor DNA by fragment size analysis
Mouliere, F., Chandrananda, D., Piskorz, A. M., Moore, E. K., Morris, J., Ahlborn, L. B., Mair, R., Goranova, T., Marass, F., Heider, K., et al. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aat4921 · Cited by 1,069
Self-citationLiquid biopsy: current technology and clinical applications
Nikanjam, M., Kato, S., & Kurzrock, R. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01351-y · Cited by 931
Liquid biopsy: a step closer to transform diagnosis, prognosis and future of cancer treatments
Lone, S. N., Nisar, S., Masoodi, T., Singh, M., Rizwan, A., Hashem, S., El-Rifai, W., Bedognetti, D., Batra, S. K., Haris, M., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01543-7 · Cited by 819
Metadata
- Authors
- Parkinson, C. A., Gale, D., Piskorz, A. M., Biggs, H., Hodgkin, C., Addley, H., Freeman, S., Moyle, P., Sala, E., Sayal, K., Hosking, K., Gounaris, I., Jimenez-Linan, M., Earl, H. M., Qian, W., Rosenfeld, N., & Brenton, J. D.
- Venue
- PLOS Medicine
- Publisher
- Public Library of Science (PLoS)
- Published
- 2016-12-20
- Volume
- 13
- Issue
- 12
- Pages
- e1002198
- ISSN
- 1549-1277 (ISSN-L)
- 1549-1676
- OpenAlex
- W2561358247
- Cited by
- 297
- References
- 50
- FWCI
- 31.84
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.